Skip to main content

3 Result(s)

within Victoria E R Parker Remove this filter

and
Your search also matched 1 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA

Include preview-only content

  1. Article

    Open Access

    Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

    Zibotentan, a selective endothelin A receptor antagonist, is in development for chronic liver and kidney disease. The pharmacokinetics (PK) of zibotentan were previously investigated in patients with either re...

    Anne-Kristina Mercier, Mikael Sunnåker, Sebastian Ueckert… in Clinical Pharmacokinetics (2023)

    Download PDF (928 KB) View Article

  2. Article

    Open Access

    Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes

    Cotadutide is a dual glucagon-like peptide 1 and glucagon receptor agonist under development for the treatment of non-alcoholic steatohepatitis and type 2 diabetes mellitus (T2DM) and chronic kidney disease. N...

    Victoria E. R. Parker, Darren Robertson, Edmundo Erazo-Tapia… in Nature Metabolism (2023)

    Download PDF (4815 KB) View Article

  3. Article

    Open Access

    Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling

    Mutations in PIK3CA are very frequent in cancer and lead to sustained PI3K pathway activation. The impact of acute expression of mutant PIK3CA during early stages of malignancy is unknown. Using a mouse model to ...

    Inma M. Berenjeno, Roberto Piñeiro, Sandra D. Castillo… in Nature Communications (2017)

    Download PDF (3663 KB) View Article